STOCK TITAN
  1. Home
  2. News
  3. ARVN

Arvinas, Inc - ARVN STOCK NEWS

Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.

Arvinas, Inc. (Nasdaq: ARVN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat debilitating and life-threatening diseases through the degradation of disease-causing proteins. The company's proprietary PROTAC® Discovery Engine platform creates Proteolysis-Targeting Chimeras (PROTACs), which leverage the cell's natural protein disposal system to target and degrade specific proteins involved in various diseases.

Founded on groundbreaking research from Yale University by Dr. Craig Crews, Arvinas is at the forefront of transforming protein degradation into novel therapeutic strategies. Their lead candidates include bavdegalutamide (ARV-110) and ARV-766, aimed at treating metastatic castration-resistant prostate cancer, and vepdegestrant (ARV-471), which targets estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Recent achievements highlight Arvinas' robust pipeline and strategic partnerships. In collaboration with Pfizer, vepdegestrant is undergoing Phase 3 trials, showing promising clinical activity and safety in heavily pre-treated breast cancer patients. The company has also initiated a strategic license agreement with Novartis for the global development and commercialization of ARV-766, affirming its potential as a first-in-class treatment for prostate cancer.

Financially, Arvinas maintains a strong position with sufficient resources to fund operations into 2027, bolstered by strategic collaborations and revenue from ongoing license agreements. The company's focus on expanding its clinical trials and exploring new combination therapies positions it for significant impact in oncology and beyond.

For the latest updates on Arvinas' developments and clinical trials, visit their website at www.arvinas.com.

News

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Rhea-AI Summary
Arvinas, Inc. appoints Dr. Noah Berkowitz as Chief Medical Officer, grants him an inducement package, and bids farewell to Dr. Ron Peck. Dr. Berkowitz brings extensive experience in clinical development and regulatory affairs from Bristol-Myers Squibb and Novartis, enhancing Arvinas' ongoing programs in oncology and neuroscience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
management
-
News

Arvinas to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Arvinas, Inc. (ARVN) announces participation in three investor conferences where key executives will present and engage with investors. The company continues to showcase its advancements in targeted protein degradation drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
-
News

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Arvinas, Inc. (ARVN) reports on clinical studies progress, financial results, and corporate updates. Vepdegestrant shows promising results in breast cancer treatment. ARV-766 demonstrates efficacy in mCRPC. The company received FDA Fast Track designation for vepdegestrant. Financially, Arvinas has a strong cash position, with $1,266.5 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
earnings
News

Arvinas Announces Chief Financial Officer Transition

Rhea-AI Summary
Arvinas, Inc. announces the departure of CFO Sean Cassidy, with Randy Teel, Ph.D., stepping in as interim CFO. The company is conducting a search for a permanent replacement. Arvinas is a biotech firm specializing in targeted protein degradation drugs, with promising clinical trials and strong financial standing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.73%
Tags
none
-
News

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

Rhea-AI Summary
Arvinas, Inc. announced dosing the first subject in the Phase 1 trial of ARV-102, a novel oral PROTAC protein degrader targeting LRRK2 for neurodegenerative diseases. The drug has shown promising results in preclinical studies, crossing the blood-brain barrier and degrading LRRK2 by nearly 90%. The Phase 1 trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
-
News

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

Rhea-AI Summary
Arvinas, Inc. and Pfizer Inc. have announced that the FDA granted Fast Track designation for vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Vepdegestrant is a novel oral PROTAC® ER degrader being jointly developed by Arvinas and Pfizer, with the potential to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The Phase 3 VERITAC-2 clinical trial is evaluating vepdegestrant or fulvestrant in patients with locally advanced or metastatic ER+/HER2- breast cancer who have been previously treated with an endocrine-based therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.85%
Tags
clinical trial
News

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

Rhea-AI Summary
Arvinas, Inc. (ARVN) announced the participation of its Chief Medical Officer and Senior Vice President in a fireside chat at the 6th Annual Guggenheim Biotechnology Conference. The event will take place on February 7 in New York, with a live audio webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences
-
News

Arvinas Appoints Jared Freedberg as General Counsel

Rhea-AI Summary
Arvinas, Inc. appoints Jared Freedberg, J.D. as General Counsel, granting him an option to purchase 67,314 shares of common stock and a restricted stock unit award with respect to 45,504 shares of common stock. The option and restricted stock units were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' stock incentive plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.51%
Tags
management
-
News

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

Rhea-AI Summary
Arvinas, Inc. (ARVN) to discuss vepdegestrant (ARV-471) data presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) and plans to expand the vepdegestrant development program in a conference call and webcast with Pfizer Inc. (PFE).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.77%
Tags
conferences
News

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

Rhea-AI Summary
Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) announced clinical data for vepdegestrant (ARV-471), a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib (IBRANCE®). The data showed a 42% overall response rate and a median progression-free survival of 11.1 months in heavily pre-treated patients with ER+/HER2- breast cancer. Pending additional data, Arvinas and Pfizer plan to broaden development of vepdegestrant to include new combinations with CDK inhibitors in both the first- and second-line settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
clinical trial

FAQ

What is the current stock price of Arvinas (ARVN)?

The current stock price of Arvinas (ARVN) is $18.48 as of December 20, 2024.

What is the market cap of Arvinas (ARVN)?

The market cap of Arvinas (ARVN) is approximately 1.2B.

What does Arvinas, Inc. specialize in?

Arvinas specializes in developing therapies that degrade disease-causing proteins using their proprietary PROTAC® platform.

What are Arvinas' lead product candidates?

Arvinas' lead candidates include bavdegalutamide (ARV-110) and ARV-766 for prostate cancer, and vepdegestrant (ARV-471) for ER+/HER2- breast cancer.

What recent partnerships has Arvinas entered?

Arvinas has partnered with Pfizer for the co-development of vepdegestrant and entered a strategic license agreement with Novartis for ARV-766.

What financial position does Arvinas hold for its future operations?

Arvinas has a strong financial position, with sufficient resources to fund operations into 2027, supported by strategic collaborations and ongoing revenue.

What is PROTAC®?

PROTAC® stands for Proteolysis-Targeting Chimeras, a technology that leverages the cell’s natural protein disposal system to target and degrade specific proteins.

How does vepdegestrant (ARV-471) work?

Vepdegestrant (ARV-471) is designed to degrade the estrogen receptor in ER+/HER2- breast cancer, using the PROTAC® mechanism to harness the body's protein disposal system.

What are the key achievements of Arvinas recently?

Key achievements include initiating Phase 3 trials for vepdegestrant, strategic collaboration with Pfizer, and a license agreement with Novartis for ARV-766.

What is the significance of Arvinas' collaboration with Pfizer?

The collaboration with Pfizer aims to co-develop and commercialize vepdegestrant, leveraging both companies' expertise to bring new cancer treatments to market.

What diseases is Arvinas targeting with its therapies?

Arvinas is targeting various cancers, including prostate cancer and breast cancer, through the degradation of disease-causing proteins.

Where can I find more information about Arvinas?

More information about Arvinas can be found on their official website at www.arvinas.com.

Stock ARVN logo
Arvinas, Inc

Nasdaq:ARVN

ARVN Rankings

#2357 Ranked by Market Cap
N/A Ranked by Dividends

ARVN Stock Data

1.22B
62.43M
7.22%
109.24%
12.43%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW HAVEN